Opportunity Information: Apply for PAR 16 055
Apply for PAR 16 055
- The HHS-NIH11 in the education, health sector is offering a public funding opportunity titled "Mechanism for Time-Sensitive Drug Abuse Research (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279,.
- This funding opportunity was created on Dec 10, 2015 and posted on Dec 10, 2015.
- Applicants must submit their applications by Nov 08, 2018. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Mechanism for Time-Sensitive Drug Abuse Research (R21) grant opportunity (PAR 16-055) is a National Institutes of Health (NIH) funding announcement, under the U.S. Department of Health and Human Services, designed to support small, rapid, and targeted studies when a drug-related public health situation is moving quickly and the window to learn from it could close soon. The intent is to fund pilot, feasibility, or exploratory projects in substance use epidemiology and health services research where investigators can clearly show that the question is time-sensitive, that waiting for a normal funding cycle would make the study less informative or impossible, and that an expedited review and award timeline is necessary to capture critical data while the opportunity exists.
The FOA focuses on five priority areas where sudden changes or new policies can create urgent research needs. First, it supports research responding to sudden and severe emerging drug issues, such as an unexpected spike in overdoses or harms from a particular substance in a defined community (an example given is a rapid increase in synthetic cannabinoid use and overdose events). Second, it supports rapid studies on emerging marijuana trends, especially topics tied to changing laws and the broader policy landscape, where shifts in access, commercialization, regulation, or public perception may quickly alter patterns of use and related outcomes. Third, it targets unexpected and time-sensitive prescription drug abuse research opportunities, including new state or local initiatives or policy changes that create a natural experiment and a short window to measure impacts on prescribing, misuse, diversion, treatment entry, or overdose outcomes. Fourth, it supports research tied to unexpected and time-sensitive medical system issues, such as opportunities to understand how addiction prevention, treatment, and recovery services function as the health care system evolves (for example, changes in coverage, care delivery models, integration of substance use disorder treatment into primary care, or shifts in reimbursement and service capacity). Fifth, it supports time-sensitive opportunities connected to criminal or juvenile justice systems, including new system-level or structural changes that affect drug use, justice involvement, and access to health services, such as reforms in diversion, sentencing, treatment in correctional settings, reentry services, or cross-system coordination.
Because this is an R21 mechanism, the scope is meant to be exploratory rather than a large, long-term definitive trial. Projects should typically be structured to quickly generate actionable evidence, test methods, establish feasibility, or produce early findings that can guide a larger study or inform near-term decisions by public health, health care, or justice stakeholders. A central expectation is that applicants will justify why the research cannot be delayed, describing what specific data or conditions would be lost if the study started later and how the proposed timeline enables capturing the event, policy rollout, or system change while it is unfolding.
Eligibility is broad and includes many types of organizations that may be positioned to respond quickly to local or regional events. Eligible applicants include state, county, city, township, and special district governments; independent school districts; public and private institutions of higher education; federally recognized tribal governments and other tribal organizations; public housing authorities and Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (excluding higher education institutions in those categories as specified); for-profit organizations other than small businesses; small businesses; and other entities as allowed under additional eligibility language in the announcement.
The FOA is listed under CFDA numbers 93.279 and is categorized as a discretionary grant in the education and health activity area. The posted information indicates an award ceiling of $200,000. The opportunity was created and posted on December 10, 2015, and the listed closing date for the cycle shown is November 8, 2018. Overall, the program is built for situations where rapid scientific learning can directly support timely public health and systems responses to emerging substance use problems, policy shifts, and structural changes affecting prevention, treatment, and service access.
Frequently Asked Questions (FAQs)
What is the Mechanism for Time-Sensitive Drug Abuse Research (R21) opportunity (PAR 16-055)?
PAR 16-055 is a National Institutes of Health (NIH) funding announcement under the U.S. Department of Health and Human Services. It supports small, rapid, and targeted research studies when a drug-related public health situation is moving quickly and the chance to learn from it may disappear if researchers wait for a standard funding cycle.
What is the main purpose of this grant?
The main purpose is to fund pilot, feasibility, or exploratory projects in substance use epidemiology and health services research that are clearly time-sensitive. Applicants are expected to show that a standard review and award timeline would make the project less informative or even impossible, and that a faster timeline is needed to capture critical data while the opportunity exists.
What kinds of studies does the FOA prioritize?
The FOA prioritizes rapid studies tied to sudden changes, emerging events, or new policies that create urgent research needs and a short window to collect meaningful information. The projects are intended to generate actionable evidence quickly, test methods, establish feasibility, or produce early findings that can guide a larger study or support near-term decision-making.
What are the five priority areas supported by this FOA?
The FOA focuses on five priority areas:
- Sudden and severe emerging drug issues (for example, unexpected spikes in overdoses or harms in a defined community, including rapid increases in synthetic cannabinoid use and overdose events).
- Emerging marijuana trends tied to changing laws and policy landscapes (for example, shifts in access, commercialization, regulation, or public perception that may quickly change use patterns and outcomes).
- Unexpected and time-sensitive prescription drug abuse research opportunities (for example, state or local initiatives or policy changes that create a natural experiment with a short window to measure impacts).
- Unexpected and time-sensitive medical system issues (for example, changes in coverage, care delivery models, integration into primary care, reimbursement changes, or shifts in service capacity affecting prevention, treatment, and recovery).
- Time-sensitive opportunities in criminal or juvenile justice systems (for example, reforms affecting diversion, sentencing, treatment in correctional settings, reentry services, or cross-system coordination and access to health services).
What does "time-sensitive" mean in the context of this grant?
In this FOA, "time-sensitive" means the research question depends on conditions that may change quickly, such as an emerging drug threat, a policy rollout, or a system-level reform. Applicants are expected to explain what specific data, circumstances, or learning opportunity would be lost if the study started later and why waiting for a normal funding cycle would reduce the value of the research or make it infeasible.
Why does the FOA emphasize an expedited review and award timeline?
The FOA is designed for situations where events unfold fast. An expedited review and award timeline is emphasized because the research must often begin while the event, policy change, or system change is occurring in order to capture real-time impacts and collect critical data before the window closes.
Is this grant intended for large, long-term clinical trials?
No. Because this is an R21 mechanism, the expected scope is exploratory rather than a large, long-term definitive trial. Projects should be designed to move quickly and produce early or feasibility-type evidence.
What types of outcomes or impacts might be studied under the prescription drug abuse priority area?
The FOA indicates that time-sensitive prescription drug abuse opportunities may involve measuring impacts on prescribing, misuse, diversion, treatment entry, or overdose outcomes, especially when a new policy or initiative creates a natural experiment with a short evaluation window.
What types of health system changes are relevant to the medical system priority area?
The FOA highlights changes such as coverage changes, new care delivery models, integration of substance use disorder treatment into primary care, reimbursement changes, and shifts in service capacity. The focus is on understanding how prevention, treatment, and recovery services function as the health care system evolves, when an unexpected opportunity arises and the timing matters.
What types of justice system changes are relevant under this FOA?
The FOA includes time-sensitive opportunities tied to criminal or juvenile justice systems, including reforms and structural changes that affect drug use, justice involvement, and access to health services. Examples include changes in diversion, sentencing, treatment in correctional settings, reentry services, and cross-system coordination.
Who is eligible to apply?
Eligibility is broad. Eligible applicants include:
- State, county, city, township, and special district governments
- Independent school districts
- Public and private institutions of higher education
- Federally recognized tribal governments and other tribal organizations
- Public housing authorities and Indian housing authorities
- Nonprofit organizations with or without 501(c)(3) status (excluding higher education institutions in those categories as specified)
- For-profit organizations other than small businesses
- Small businesses
- Other entities as allowed under additional eligibility language in the announcement
What research fields does this FOA emphasize?
The FOA emphasizes substance use epidemiology and health services research, with an emphasis on rapid, targeted studies that address emerging substance use problems and system or policy shifts.
How should an applicant justify that their project cannot be delayed?
Applicants are expected to justify why the research cannot be delayed by describing what specific data or conditions would be lost if the study started later, and how the proposed timeline enables capturing the event, policy rollout, or system change while it is unfolding.
What is the award ceiling listed for this opportunity?
The posted information indicates an award ceiling of $200,000.
What are the CFDA numbers associated with this FOA?
This opportunity is listed under CFDA numbers 93.279.
How is this grant categorized?
The FOA is categorized as a discretionary grant in the education and health activity area.
When was this opportunity created and posted?
The opportunity was created and posted on December 10, 2015.
What is the listed closing date for the cycle shown?
The listed closing date for the cycle shown is November 8, 2018.
What is an example of a "sudden and severe emerging drug issue" mentioned in the FOA?
An example given is a rapid increase in synthetic cannabinoid use and overdose events in a defined community.
What is meant by a "natural experiment" in this FOA?
The FOA uses the term in the context of policy or initiative changes (especially around prescription drug abuse) that create an unexpected, real-world opportunity to measure impacts within a short time window.
What kinds of decisions can these studies inform?
The FOA indicates that projects should quickly generate evidence that can inform near-term decisions by public health, health care, or justice stakeholders, particularly when responding to emerging substance use problems, policy shifts, and structural changes affecting prevention, treatment, and service access.
Browse more opportunities from the same agency: HHS-NIH11
Browse more opportunities from the same category: Education, Health
Next opportunity: Cooperative Agreements for Adolescent and Transitional Aged Youth Treatment Implementation [Youth Treatment – Implementation (Short Title –YT-I)]
Previous opportunity: INSTITUTES FOR HISTORICAL EDITING
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 16 055
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 16 055) also looked into and applied for these:
| Funding Opportunity |
|---|
| Small Cell Lung Cancer (SCLC) Consortium: Coordinating Center (U24 ) Apply for PAR 16 050 Funding Number: PAR 16 050 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $800,000 |
| Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33) Apply for RFA CA 16 002 Funding Number: RFA CA 16 002 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $300,000 |
| Advanced Development and Validation of Emerging Technologies for Cancer-Relevant Biospecimen Science (R33) Apply for RFA CA 16 004 Funding Number: RFA CA 16 004 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $300,000 |
| Small-Cell Lung Cancer (SCLC) Consortium: Therapeutic Development and Mechanisms of Resistance (U01) Apply for PAR 16 049 Funding Number: PAR 16 049 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $450,000 |
| Genomic Data Analysis Network: Processing Genomic Data Center (U24) Apply for RFA CA 15 018 Funding Number: RFA CA 15 018 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $660,000 |
| Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate the Discovery of Neurotherapeutics (R21/R33) Apply for RFA NS 16 013 Funding Number: RFA NS 16 013 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $250,000 |
| Small-Cell Lung Cancer (SCLC) Consortium: Innovative Approaches to the Prevention and Early Detection of Small Cell Lung Cancer (U01) Apply for PAR 16 051 Funding Number: PAR 16 051 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $450,000 |
| Examination of Survivorship Care Planning Efficacy and Impact (R01) Apply for PA 16 012 Funding Number: PA 16 012 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Proteome Characterization Centers for Clinical Proteomic Tumor Analysis Consortium (U24) Apply for RFA CA 15 021 Funding Number: RFA CA 15 021 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $800,000 |
| Innovative Questions in Symptom Science and Genomics (R15) Apply for PA 16 022 Funding Number: PA 16 022 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $300,000 |
| Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01) Apply for PA 16 035 Funding Number: PA 16 035 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Drug Discovery For Nervous System Disorders (R21) Apply for PAR 16 042 Funding Number: PAR 16 042 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Revision Applications for Assay Validation For High Quality Markers For NCI-Supported Clinical Trials (U10) Apply for PAR 16 056 Funding Number: PAR 16 056 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $150,000 |
| Innovative Questions in Symptom Science and Genomics (R01) Apply for PA 16 024 Funding Number: PA 16 024 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Global Noncommunicable Diseases and Injury Across the Lifespan: Exploratory Research (R21) Apply for PAR 16 052 Funding Number: PAR 16 052 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $125,000 |
| Integration of Infectious Diseases and Substance Abuse Intervention Services for Individuals Living with HIV (R01) Apply for RFA DA 16 011 Funding Number: RFA DA 16 011 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Innovative Questions in Symptom Science and Genomics (R21) Apply for PA 16 023 Funding Number: PA 16 023 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01) Apply for PAR 16 059 Funding Number: PAR 16 059 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $450,000 |
| Applying Metabolomics to Drive Biomarker Discovery in Symptom Science (R01) Apply for PA 16 030 Funding Number: PA 16 030 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21) Apply for RFA CA 16 001 Funding Number: RFA CA 16 001 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 16 055", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.